Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3698331 | 0.89 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL11844930 | 0.89 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL15233756 | 0.89 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL2270514 | 0.86 | SHBG (0.38) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL15233755 | 0.80 | — | — | |
| SCHEMBL12065455 | 0.78 | SHBG (0.34) | SHBGEPHX1 | |
| SCHEMBL20492121 | 0.78 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL8620129 | 0.78 | SHBG (0.42) | SHBGEPHX1CA12CA1CA2 | |
| SCHEMBL18914139 | 0.77 | SHBG (0.32) | SHBG | |
| SCHEMBL10063341 | 0.77 | SHBG (0.43) | SHBGEPHX1TP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | BAYER SCHERING PHARMA AG (DE) | 2009-05-21 | — | — | US | disclosed |
| EP-2036578-A1 | Diagnostic agents for positron emission imaging using F-18 radio labeled amino-alcohols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090130020-A1 | DIAGNOSTIC AGENTS FOR POSITRON EMISSION IMAGING USING F-18 RADIO-LABELED AMINO-ALCOHOLS | ADH1A, ADH5, FABP1 | SHBG 1480/4885EPHX1 3186/4885CA12 192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.